https://www.selleckchem.com/pr....oducts/harringtonine
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We present primary completion analysis from RIVETING, an ongoing, double-blind, randomized, parallel-group trial evaluating efficacy and safety of tofacitinib dose reduction to 5mg twice daily [BID] versus remaining on 10mg BID in patients in stable remission on tofacitinib 10mg BID maintenance therapy. Patients had received tofacitinib 10mg BID for ≥2 consecutive years and been in stable remission for ≥6 months before enrollment
Like
Comment
Share
